The menopausal transition
|
|
- Rebecca Stevens
- 7 years ago
- Views:
Transcription
1 The menopausal transition Practice Committee of the American Society for Reproductive Medicine The American Society for Reproductive Medicine, Birmingham, Alabama This Committee Opinion outlines the stages of the menopausal transition, as defined by the July 2001 Stages of Reproductive Aging Workshop (STRAW). (Fertil Steril Ò 2008;90:S61 5. Ó2008 by American Society for Reproductive Medicine.) DEFINITIONS As defined by the Stages of Reproductive Aging Workshop (STRAW) held in July 2001, the menopausal transition (MT) begins with variations in menstrual cycle length and a monotropic rise in follicle-stimulating hormone (FSH; no associated increase in luteinizing hormone [LH]), and ends with the final menstrual period, classically confirmed only when followed by 12 months of amenorrhea (1). The perimenopause, which literally means about or around the menopause, begins at the same time as the MT and ends 1 year after the final menstrual period (Fig. 1). The median age at the final menstrual period is 51.4 years (2). The STRAW report, based on the proceedings of a consensus conference, further classifies reproductive and postreproductive life into seven stages, with the MT accounting for two of those stages (1). The anchor for the staging system is the final menstrual period, and the age range and duration for each of the stages varies. Five stages precede ( ), and two follow (þ), the final menstrual period. A modified menopausal staging system (PENN-5) has attempted to refine the STRAW staging system by adding an eighth stage that further subdivides the early MT (3). In the early MT (stage 2), previously regular menstrual cycles become more variable and cycle length (intermenstrual interval) changes by 7 days or more. The late MT (stage 1) is characterized by two or more missed menstrual periods, at least one intermenstrual interval of 60 days or more, and an FSH level greater than 40 IU/L (4). Menopause is determined in retrospect after a year of amenorrhea (1, 5). For women with at least one intermenstrual interval of 60 days or more, the median time to menopause is 2.6 to 3.3 years (6). For women over the age of 45 having a year of amenorrhea, there is a 90% probability that they will not have another spontaneous menstrual period (7). Cigarette smoking may alter the ovarian aging process and advances the age of menopause by as much as 2 years (8). ENDOCRINE CHANGES IN THE MENOPAUSAL TRANSITION Secretion of reproductive hormones during the MT previously was thought to decline progressively in a linear fashion, Committee Opinion Revised January No reprints will be available. but hormone levels have since been shown to fluctuate widely. Studies in large cohorts of women have demonstrated that circulating FSH concentrations rise progressively during the MT (9 11). The monotropic rise in FSH is attributed to a decrease in ovarian inhibin secretion rather than to a decrease in estradiol production (11 13). In perimenopausal women, estradiol production fluctuates with FSH levels and can reach higher concentrations than those observed in young women under age 35 (14, 15). Estradiol levels generally do not decrease significantly until late in the MT (15, 16). Despite continuing regular cyclic menstruation, progesterone levels during the early MT are lower than in women of midreproductive age and vary inversely with body mass index (11). Women in the late MT exhibit impaired folliculogenesis and an increasing incidence of anovulation, compared to midreproductive-aged women (13). Testosterone levels do not vary appreciably during the MT (10). Inhibin and activin are proteins produced by the granulosa cells and have been shown to play major roles during the MT. The inhibin molecule consists of a covalently-bound dimer having an a subunit and one of two different b subunits, designated as b A and b B ; the resulting heterodimers are known as inhibin A and inhibin B. Inhibin A is secreted by the corpus luteum and inhibin B by antral and dominant follicles. Consequently, inhibin A levels increase during the luteal phase, and inhibin B concentrations rise during the follicular phase. Both inhibins inhibit pituitary FSH secretion. Activins are a related class of proteins that stimulate pituitary FSH release and derive from the combination of two inhibin b subunits. The activin molecule is a homodimer composed of two covalently linked inhibin b subunits, designated as activin A (b A b A) and activin B (b B b B ). Antim ullerian hormone (AMH) is secreted by the granulosa cells of secondary and preantral follicles. Circulating concentrations remain relatively stable across the menstrual cycle and correlate with the number of early antral follicles. Levels of AMH decrease markedly and progressively across the MT (17). During the late reproductive stage (stage 3), follicular phase inhibin B levels decrease as FSH concentrations rise (9, 12, 18). As the MT progresses, luteal phase inhibin A levels also decline (13). Activin A concentrations also are elevated in perimenopausal women (19, 20). Whereas activins clearly play a local role in regulating pituitary FSH secretion, /08/$34.00 Fertility and Sterility â Vol. 90, Suppl 3, November 2008 S61 doi: /j.fertnstert Copyright ª2008 American Society for Reproductive Medicine, Published by Elsevier Inc.
2 FIGURE 1 Stages/nomenclature of normal reproductive aging in women. The stages of reproductive aging in women in relation to the final menstrual period, defined as Stage 0. Stage 5: the early reproductive stage. Stage 4: the peak reproductive stage. Stage 3: the late reproductive stage. Stage 2: the early menopausal transition. Stage 1: the late menopausal transition. Stage þ1a: the first year after the final menstrual period. Stage þ1b: years 2 to 5 after menopause. Stage þ2: the later postmenopausal years. Recommendations of Stages of Reproductive Aging Workshop (STRAW), Park City, Utah, July (Reprinted with permission from the American Society for Reproductive Medicine. Fertility and Sterility, 2001, Vol. 76, No. 5, page 875). ASRM Practice Committee. Menopausal Transition. Fertil Steril their ability to act as endocrine factors to influence the production of FSH has not been established. Thus, a decrease in secretion of inhibin A and inhibin B, and a corresponding increase in activin production may favor increased FSH secretion in the absence of any decrease (and perhaps an increase) in estradiol production. HORMONAL TESTING FOR EVIDENCE OF MENOPAUSAL TRANSITION Diagnosis of the MT is based on clinical signs and symptoms. Although hormonal changes occur during the MT, hormone measurements are not useful for predicting the stage of MT or the final menstrual period. The monotropic rise in FSH associated with menopause becomes evident during the early follicular phase of the menstrual cycle in many women over age 40 and has been associated with a poor prognosis for future fertility (21). However, FSH levels can vary significantly across cycles, and the utility of FSH levels for predicting menopause in individual women is therefore low (4, 14). Symptoms similar to those associated with the MT may be observed in numerous other disorders. Specific evaluation to exclude hypothyroidism or depression may be warranted because these common conditions often emerge during the MT. MANAGEMENT AND TREATMENT OF SYMPTOMS DURING THE MENOPAUSAL TRANSITION Much of the available information about the MT derives from the ongoing Study of Women s Health Across the Nation (SWAN), a multiethnic, community-based, longitudinal study of perimenopausal women at seven sites throughout the United States (4, 6, 10, 11). Most women who are symptomatic during the MT present with frequent or excessive bleeding or with hot flashes and other symptoms of estrogen deficiency. Abnormal uterine bleeding is common during the MT, particularly once menses become irregular and unpredictable. Because the time interval surrounding menopause is characterized by relatively high, acyclic estrogen levels and relatively low progesterone production, women in the MT are at some increased risk for developing endometrial hyperplasia or carcinoma. Among premenopausal women over age 45 with abnormal uterine bleeding, the risk for endometrial hyperplasia or cancer is increased three-fold (OR 3.1; 95% CI, ) and the overall prevalence is 7.9% (22 cases out of 280 patients) (22). Abnormal bleeding may be controlled effectively with combination oral contraceptive pills, provided the patient does not smoke and has no other contraindications. Although still frequently prescribed, a systematic review concluded that cyclic administration of medroxyprogesterone acetate is ineffective for the treatment for bleeding during the menopausal transition (23). A progestin-containing intrauterine device (IUD) is another option that offers both control over bleeding and contraception (24), but its use is not approved for this indication by the U.S. Food and Drug Administration (FDA). Changes in hormone secretion during the MT are associated with a number of symptoms, the most common being hot flashes. The prevalence of hot flashes increases as the MT progresses and reaches a high of about 63% during the S62 ASRM Practice Committee Menopausal Transition Vol. 90, Suppl 3, November 2008
3 late menopausal transition (25 27). Vasomotor symptoms before or at the onset of the MT are common, affecting up to 39% of women, but they are usually well tolerated (28). Longitudinal studies have shown that hot flashes are associated with low exercise levels, smoking, high FSH and low estradiol levels (29), increasing body mass, ethnicity, socioeconomic status, and a history of premenstrual dysphoric disorder (PMDD) or depression (30). Depressed mood disorders also are increased during the MT. Community-based surveys have shown that perimenopausal women report significantly more psychological distress and have an increased risk for significant depression, compared with premenopausal or postmenopausal women (31, 32). In an 8-year longitudinal study of premenopausal women having no prior history of depression, a depressive disorder was more likely to be diagnosed during the MT than in the premenopausal years (OR, 2.5; 95% CI, , P¼.01) (33). Sleep disturbances also are very common during the MT. In longitudinal studies of perimenopausal women, the prevalence of sleep disturbances has ranged from 32% to 40% in the early MT and from 38% to 46% in the late MT (27, 34). Other common symptoms during the MT include decreased libido, forgetfulness, vaginal dryness, and urinary incontinence (35, 36). Vasomotor symptoms during the MT can be treated with hormone therapy (HT) using estrogen or progestin alone or in combination, neuroactive agents, or other nonhormonal alternatives. Estrogen therapy provides the best treatment for severe vasomotor symptoms, reducing their frequency and severity in 80% to 85% of women over 12 weeks compared with 30% of women receiving placebo (37). Hormone therapy also may help in the management of depression associated with the MT. In a randomized, placebo-controlled, 12-week trial involving perimenopausal women ages 40 to 55, symptoms of depression were improved in 68% of women receiving unopposed estrogen treatment (0.1 mg transdermal estradiol patch), compared with 20% of those receiving placebo (P¼.001) (38). Long-term use of HT in older menopausal women has been associated with increased risks for venous thromboembolism, coronary events, stroke, and breast cancer (39, 40). Although short-term treatment of symptomatic women during the MT likely poses significantly fewer risks, HT generally should be used in the lowest effective dose and for the shortest time required. Low-dose estrogen regimens (conjugated equine estrogens, 0.3 mg daily, or its equivalent) can achieve as much as a 75% reduction in vasomotor symptoms over 12 weeks, approaching the efficacy of standard-dose HT regimens, and may be associated with fewer risks and side effects (41). The decision to use HT should be made only after first carefully reviewing its risks and benefits for the individual. The relative safety of HT during the MT has not been thoroughly investigated. The results of one observational study Fertility and Sterility â have suggested that women who start HT near menopause had a decreased risk of coronary heart disease when taking estrogen alone (relative risk [RR] ¼ 0.66; 95% CI, ) or in combination with progestin (RR ¼ 0.72; 95% CI, ) (42). A secondary analysis conducted by the investigators involved in the Women s Health Initiative (WHI) revealed that risk for coronary heart disease was not significantly increased in women under age 60 years of age or within 10 years of menopause (43). Further studies to evaluate the safety and efficacy of HT during the MTand the early postmenopausal years are ongoing (44). Concerns about the risks of HT have increased interest in nonhormonal alternatives for the treatment of symptoms in the MT. In some women, vasomotor symptoms during the MT can be reduced by wearing layered clothing, avoiding caffeine and alcohol, and by keeping the ambient temperature a few degrees cooler. Herbal treatments such as black cohosh (Remifemin Menopause â ; Enzymatic Therapy, Green Bay, WI) have been shown to have marginal or no benefit in placebo-controlled trials (37, 45). Neuroactive agents, including selective serotonin reuptake inhibitors (SSRIs), serotoninnorepinephrine reuptake inhibitors (SNRIs), alpha adrenergic agents, and others all have some efficacy in the treatment of vasomotor symptoms (Table 1). Both SSRIs and SNRIs may be effective because norepinephrine and serotonin appear to be involved in the TABLE 1 Nonhormonal alternatives for treatment of hot flashes. Class of drug Name Dose SSRI Citalopram Fluoxetine Sertraline Paroxetine SNRI Venlafaxine Desvenlafaxine Alphaadrenergic agents Gamma amino butyric acid succinate Clonidine 0.1 transdermally Gabapentin Note: These alternatives are not U.S. FDA approved for treatment of hot flashes. ASRM Practice Committee. Menopausal Transition. Fertil Steril S63
4 hypothalamic regulation of temperature homeostasis and to play a role in the development of hot flashes. Randomized placebo-controlled trials have shown that SSRIs (citalopram, sertraline, paroxetine) and SSNIs (venlafaxine) can help to reduce the severity and frequency of hot flushes (46, 47). Clonidine (an alpha adrenergic agonist) and gabapentin also have some efficacy (46, 47). However, the effectiveness of neuroactive therapies does not equal that of HT. Given that the onset of menopause cannot be predicted precisely, that women may ovulate up until their final menses, and that prescription drugs and alternative therapies may have potential adverse effects on pregnancy, clinicians should remain sensitive to the contraceptive needs of women during the MT. SUMMARY AND CONCLUSIONS The menopausal transition that precedes the final menstrual period varies in length, is characterized by variations in cycle length, and commonly is associated with frequent or excessive bleeding and hot flashes. The treatment of women during the menopausal transition should be based primarily on the frequency and severity of their symptoms. Hormone measurements during the menopausal transition are imprecise and cannot predict menopause. After a diagnostic evaluation has been completed, medical treatment of abnormal uterine bleeding during the menopausal transition may include the use of lowdose combination oral contraceptives, estrogens/progestogens, and progestin-containing IUDs. Overall, HT remains the most effective treatment for hot flashes. Acknowledgments: This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. This committee opinion was accepted by the Practice Committee of the American Society for Reproductive Medicine and approved by the Board of Directors of the American Society for Reproductive Medicine. REFERENCES 1. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76: McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14: Gracia CR, Sammel MD, Freeman EW, Lin H, Langan E, Kapoor S, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005;12: Randolph JF, Crawford S, Dennerstein L, Cain K, Harlow SD, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab 2006;91: Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for application in epidemiologic investigations. Am J Epidemiol 1994;140: Harlow SD, Cain K, Crawford S, Dennerstein L, Little R, Mitchell ES, et al. Evaluation of four proposed bleeding criteria for the onset of the late menopausal transition. J Clin Endocrinol Metab 2006;91: Wallace RB, Sherman BM, Bean JA, Treloar AE, Schlabaugh L. Probability of menopause with increasing duration of amenorrhea in middleaged women. Am J Obstet Gynecol 1979;135: McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985;103: Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84: Randolph JF, Sowers M, Gold EB, Mohr BA, Luborsky J, Santoro N, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;88: Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, Gold EB, et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: Study of Women s Health across the Nation (SWAN) Daily Hormone Study. J Clin Endocrinol Metab 2004;89: Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996;81: Santoro N, Isaac B, Neal-Perry G, Adel T, Weingart L, Nussbaum A, et al. Impaired folliculogenesis and ovulation in older reproductive aged women. J Clin Endocrinol Metab 2003;88: Shideler SE, DeVane GW, Kalra PS, Benirschke K, Lasley BL. Ovarian pituitary hormone interactions during the perimenopause. Maturitas 1989;11: Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81: Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995;80: Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab 2007;92: Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999;84: Reame NE, Wyman TL, Phillips DJ, de Kretser DM, Padmanabhan V. Net increase in stimulatory input resulting from a decrease in inhibin B and an increase in activin A may contribute in part to the rise in follicular phase follicle-stimulating hormone of aging cycling women. J Clin Endocrinol Metab 1998;83: Santoro N, Adel T, Skurnick JH. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril 1999;71: Toner JP. The significance of elevated FSH for reproductive function. Baillieres Clin Obstet Gynaecol 1993;7: Farquhar CM, Lethaby A, Sowter M, Verry J, Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999;181: Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;2:CD Lethaby AD, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;4:CD S64 ASRM Practice Committee Menopausal Transition Vol. 90, Suppl 3, November 2008
5 25. Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol 1996;88: Mitchell ES, Woods NF, Mariella A. Three stages of the menopausal transition from the Seattle Midlife Women s Health Study: toward a more precise definition. Menopause 2000;7: Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96: Randolph JF Jr, Sowers M, Bondarenko I, Gold EB, Greendale GA, Bromberger JT, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005;90: Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. Hot flushes during the menopause transition: a longitudinal study in Australianborn women. Menopause 2005;12: Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women s health across the nation. Am J Public Health 2006;96: Bromberger JT, Meyer PM, Kravitz HM, Sommer B, Cordal A, Powell L, et al. Psychological distress and natural menopause: a multiethnic community study. Am J Public Health 2001;91: Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61: Freeman EW, Sammel MD, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63: Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003;10: Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women s lives. Am J Med 2005;118(Suppl 12B): Van Voorhis BJ. Genitourinary symptoms in the menopausal transition. Am J Med 2005;118(Suppl 12B): Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med 2006;355: Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a doubleblind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58: Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA. Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005;3:CD Practice Committee of the American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril in press. 41. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118(Suppl 12B): Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15: Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297: Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13: Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145: Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196: Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295: Fertility and Sterility â S65
Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women
Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women Irina Shestakova, MD, PhD Research Center of Obstetrics, Gynecology and Perinatology Department of
More informationDepression in the Menopause and Perimenopause
Depression in the Menopause and Perimenopause David A. Forstein, DO, FACOOG, (Dist) Associate Professor of Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Residency
More informationHormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and
Hormonal Oral Contraceptives: An Overview By Kelsie Court A variety of methods of contraception are currently available, giving men and women plenty of options in choosing a method suitable to his or her
More informationDepressive disorders among older residents in a Chinese rural community. Risk for Depression by Age and Sex. Risk for Depression by Age and Sex
Risk for Depression by Age and Sex Risk for Depression by Age and Sex Depressive disorders among older residents in a Chinese rural community. Liu CY, et al: Psychological Medicine 1997:27: 943-949 Male
More informationWOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500. Hormone Therapy
Hormone Therapy WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 At menopause, a woman's body makes less estrogen and she stops having menstrual periods. This is a natural stage in a woman's
More informationMenopause Guidance on management and prescribing HRT for GPs based on NICE guidance 2015
PRIMARY CARE WOMEN S HEALTH FORUM GUIDELINES Menopause Guidance on management and prescribing HRT for GPs based on NICE guidance 2015 Written by Dr Imogen Shaw This guidance is designed to support you
More informationHormone replacement therapy:
www.bpac.org.nz keyword: hrt Hormone replacement therapy: latest evidence and treatment recommendations Key advisor: Dr Helen Roberts, Senior Lecturer, Department of Obstetrics and Gynaecology, Faculty
More informationThe Value of Follicle-Stimulating Hormone Concentration and Clinical Findings as Markers of the Late Menopausal Transition
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(8):3034 3040 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2006-0243 The Value of Follicle-Stimulating
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationFrom Menses to Menopause: How Hormones Can Affect Blood Glucose Levels. Christine Day, RN, MS, CNS-BC Lake Superior College
From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels Christine Day, RN, MS, CNS-BC Lake Superior College Overview Will review hormonal changes over the female lifespan Discuss the effects
More informationSmoking and Age of Menopause. Women who smoke experience menopause an average of 2 years earlier than women who do not smoke.
Menopause Menopause Feared event To many, it indicates old age - a sign of life coming to a close. Many expect a difficult psychological adjustment to menopause (bad press, bad jokes). Menopause Effect
More informationpatient education Fact Sheet PFS003: Hormone Therapy APRIL 2015
patient education Fact Sheet PFS003: Hormone Therapy APRIL 2015 Hormone Therapy Menopause is the time in a woman s life when she naturally stops having menstrual periods. Menopause marks the end of the
More informationMenopause and Hormone Replacement Therapy
Menopause and Hormone Replacement Therapy Daniel Breitkopf, MD Department of Obstetrics and Gynecology University of Texas Medical Branch Galveston, Texas USA Objectives Define the indications and contraindications
More informationDiagnosis and management of mood disorders during the menopausal transition
The American Journal of Medicine (2005) Vol 118 (12B), 93S 97S Diagnosis and management of mood disorders during the Lee S. Cohen, MD, Claudio N. Soares, MD, PhD, Hadine Joffe, MD, MSc Department of Perinatal
More informationCenter for Specialized Gynecology Susan Kaufman, DO * Jodi Benett, DO * Beverly Mikes, MD Mary Steen, NPC, APN. Hot flashes
Definition Center for Specialized Gynecology Susan Kaufman, DO * Jodi Benett, DO * Beverly Mikes, MD Mary Steen, NPC, APN Hot flashes Hot flashes can happen at any time, leaving you sweaty and red-faced.
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationAbigail R. Proffer, M.D. October 4, 2013
Abigail R. Proffer, M.D. October 4, 2013 Topics Human Papillomavirus (HPV) Vaccines Pap smears Colposcopy Contraception Polycystic Ovary Syndrome (PCOS) Can I get pregnant? Miscarriage Abnormal Uterine
More information(212) 733-2324 mackay.jimeson@pfizer.com
For immediate release: July 9, 2012 Media Contacts: MacKay Jimeson (212) 733-2324 mackay.jimeson@pfizer.com Pfizer Recognizes 10 th Anniversary Of The Women s Health Initiative: A Modern Day Perspective
More informationShira Miller, M.D. Los Angeles, CA 310-734-8864 www.shiramillermd.com. The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library
Shira Miller, M.D. Los Angeles, CA 310-734-8864 The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library 2 Outline What is hormone therapy? Why would healthy men and women need to think about
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationObesity and the Menopause. Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology
Obesity and the Menopause Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology Educational Objectives Review normal menopausal transition Review health risks of obesity
More informationPOLYCYSTIC OVARY SYNDROME
POLYCYSTIC OVARY SYNDROME Information Leaflet Your Health. Our Priority. Page 2 of 6 What is polycystic ovary syndrome? (PCOS) Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women
More informationPolycystic Ovarian Syndrome
Polycystic Ovarian Syndrome What is Polycystic Ovarian Syndrome? Polycystic ovary syndrome (or PCOS) is a common condition affecting 3 to 5% of women of reproductive age. It is linked with hormonal imbalances,
More informationKantar Health, New York, NY 2 Pfizer Inc, New York, NY. Experiencing depression. Not experiencing depression
NR1-62 Depression, Quality of Life, Work Productivity and Resource Use Among Women Experiencing Menopause Jan-Samuel Wagner, Marco DiBonaventura, Jose Alvir, Jennifer Whiteley 1 Kantar Health, New York,
More informationHull & East Riding Prescribing Committee
Hull & East Riding Prescribing Committee Guideline on Prescribing of Gonadorelin (GnRH) Analogues and Progesterone Receptor Modulators in treatment of Endometriosis or prior to Endometrial Ablation, or
More informationThe Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention
The Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention Robert B. Wallace, MD, MSc Departments of Epidemiology and Internal Medicine University of Iowa College of Public Health
More informationThe Menstrual Cycle. Model 1: Ovarian Cycle follicular cells
The Menstrual Cycle REVIEW questions to complete before starting this POGIL activity 1. Gonads produce both gametes and sex steroid hormones. For the female, name the: A. gonads ovaries B. gametes oocyte/ovum/egg
More informationManaging Menopausal Symptoms Kirsten J. Lund, M.D. Associate Professor, OB-GYN University of Colorado
Managing Menopausal Symptoms Kirsten J. Lund, M.D. Associate Professor, OB-GYN University of Colorado Disclosures No ties, financial or otherwise, to pharmaceutical companies Will identify non-fda approved
More informationDepression in the menopause transition: risks in the changing hormone milieu as observed in the general population
Freeman Women's Midlife Health (2015) 1:2 DOI 10.1186/s40695-015-0002-y REVIEW Depression in the menopause transition: risks in the changing hormone milieu as observed in the general population Ellen W.
More informationAbnormal Uterine Bleeding FAQ Sheet
Abnormal Uterine Bleeding FAQ Sheet What is abnormal uterine bleeding? Under normal circumstances, a woman's uterus sheds a limited amount of blood during each menstrual period. Bleeding that occurs between
More informationOPTIONS FOR MEDICATION
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES GYNAECOLOGY MANAGEMENT OF MENOPAUSE AFTER BREAST CANCER MANAGEMENT OF MENOPAUSAL SYMPTOMS OPTIONS FOR MEDICATION Keywords: Menopause medication, complementary
More informationDr. Friedman s Guide to Estrogen Replacement
Dr. Friedman s Guide to Estrogen Replacement There are risks and benefits with all medicines and estrogen replacement is no exception. In fact, estrogen replacement is one of the most controversial topics
More informationAbnormal Uterine Bleeding: Simple evaluation and management in premenopausal women
Objectives Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women Provide a framework to evaluate abnormal uterine bleeding (AUB) Review medical and surgical management options
More informationAnatomy and Physiology of Human Reproduction. Module 10a
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationOvarian Cyst. Homoeopathy Clinic. Introduction. Types of Ovarian Cysts. Contents. Case Reports. 21 August 2002
Case Reports 21 August 2002 Ovarian Cyst Homoeopathy Clinic Check Yourself If you have any of the following symptoms call your doctor. Sense of fullness or pressure or a dull ache in the abdomen Pain during
More informationThe Women s Health Initiative where are we a decade later?
The Women s Health Initiative where are we a decade later? Henry G. Burger MIMR-PHI Institute & Jean Hailes for Women s Health, Melbourne, Australia Disclosures: Henry Burger Sources of Funding Pharmaceutical
More informationTestosterone for women, who when and how much?
Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,
More informationPresenting Genital Symptoms and Physical Signs of Vaginal Atrophy
Sexual Health in the Menopause Presenting Genital Symptoms and Physical Signs of Vaginal Atrophy Symptoms Dryness Itching Burning Dyspareunia Signs on Physical Exam Pale, smooth, or shiny vaginal epithelium
More informationHormone Replacement Therapy For Women
Hormone Replacement Therapy For Women Bio-identical Hormone Replacement Therapy Gail Eberharter M.D. May 10, 2009 There are three main hormones that are responsible for the menstrual cycle, sexual drive
More informationNow that your Doctor has prescribed Livial for you
Now that your Doctor has prescribed Livial for you This educational brochure is only for use by patients prescribed LIVIAL The Menopause The term menopause refers to the very last menstrual period a woman
More informationLakeview Endocrinology and Diabetes Consultants. 2719 N Halsted St C-1. Chicago IL 60614 P: 773 388 5685 F: 773 388 5687. www.lakeviewendocrinolgy.
Lakeview Endocrinology and Diabetes Consultants 2719 N Halsted St C-1 Chicago IL 60614 P: 773 388 5685 F: 773 388 5687 www.lakeviewendocrinolgy.com Patient information: Early menopause (premature ovarian
More informationTopical Progesterone Studies Author Subjects Design Preparation Results. Randomized, placebocontrolled. (28 days)
Topical Progesterone Studies Author Subjects Design Preparation Results Leonetti et al, 2003: Fertil Steril,79(1), 221-222 Wren et al, 2003: Menopause, 10(1), 13-18 Vashisht et al, 2005, Gynecol Endocrinol,
More informationThe menopausal transition usually has three parts:
The menopausal transition usually has three parts: Perimenopause begins several years before a woman s last menstrual period, when the ovaries gradually produce less estrogen. In the last 1-2 years of
More informationHEALTH UPDATE. Polycystic Ovary Syndrome (PCOS)
HEALTH UPDATE PO Box 800760 Charlottesville, VA 22908 Gynecology: (434) 924-2773 Polycystic Ovary Syndrome (PCOS) What is it? An endocrine (hormonal) disorder. Because there is such variability in how
More informationA list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
More informationExecutive summary of the Stages of Reproductive Aging Workshop 10: addressing the unfi nished agenda of staging reproductive aging
CLIMACTERIC 2012;Early Online,1 10 Executive summary of the Stages of Reproductive Aging Workshop 10: addressing the unfi nished agenda of staging reproductive aging Siob á n D. Harlow PhD 1, Margery Gass
More informationReproduction and its Hormonal Control
Reproduction and its Hormonal Control Page 1 Reproduction and its Hormonal Control Different mammals have different patterns of reproduction Eg mammals, rats and mice can breed all year round, whereas
More informationAbnormal Uterine Bleeding. Howard Herrell, MD FACOG
Abnormal Uterine Bleeding Howard Herrell, MD FACOG Disclosures I, Howard Herrell, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a
More informationEXECUTIVE SUMMARY Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging
Menopause: The Journal of The North American Menopause Society Vol. 19, No. 4, pp. 000/000 DOI: 10.1097/gme.0b013e31824d8f40 * 2012 by The North American Menopause Society EXECUTIVE SUMMARY Executive summary
More informationINFERTILITY/POLYCYSTIC OVARIAN SYNDROME. Ovulatory Dysfunction: Polycystic ovarian syndrome (PCOS)
Introduction Infertility is defined as the absence of pregnancy following 12 months of unprotected intercourse. Infertility may be caused by Ovulatory Dysfunction, Blocked Fallopian Tubes, Male Factor
More informationREPRODUCTIVE aging is associated with a decline in
0021-972X/99/$03.00/0 Vol. 84, No. 1 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Female Reproductive Aging Is Marked by Decreased Secretion
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 13 October 2005 Doc. Ref. EMEA/CHMP/021/97 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationPredicting age at menopause: Hormonal, familial, and menstrual cycle factors to consider
American Society for Reproductive Medicine V o l u m e 1 9, N u m b e r 2 M ay 2 0 1 1 F o r c l i n i c i a n s w h o p r o v i d e c a r e f o r w o m e n Predicting age at menopause: Hormonal, familial,
More informationHormone replacement therapy in postmenopausal women: utilization of health care resources by new users
Hormone replacement therapy in postmenopausal women: utilization of health care resources by new users John M. Thorp Jr, MD, a Norma I. Gavin, PhD, b and Robert L. Ohsfeldt, PhD, c Chapel Hill, NC, and
More informationHOW IS OVARIAN RESERVE ASSESSED?
HOW IS OVARIAN RESERVE ASSESSED? The majority of indicators we have to assess OR assess egg quantity rather than egg quality and these two do not always go hand in hand. No individual test is a perfect
More informationTestosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone
More informationHormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions
Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions IMPORTANCE OF HORMONE BALANCE Importance of Hormone Balance Help you live a long, healthy life Help you
More informationUnderstanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
More informationACTIVITY DISCLAIMER. Menopause and Hormone Replacement Therapy: Managing Menopause: EBM Meets HRT DISCLOSURE. Learning Objectives
Menopause and Hormone Replacement Therapy: Managing Menopause: EBM Meets HRT Jennifer Frank, MD, FAAFP ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of
More informationHow To Know The Benefits And Risks Of Hormone Therapy
Menopause: The Journal of The North American Menopause Society Vol. 19, No. 3, pp. 257/271 DOI: 10.1097/gme.0b013e31824b970a * 2012 by The North American Menopause Society POSITION STATEMENT The 2012 Hormone
More informationHormone Therapy with Tamoxifen
What is hormone-receptor-positive breast cancer? Many breast cancers need estrogen and/or progesterone (female hormones), to grow and spread. When breast cancer is found, the cancer is tested for two proteins,
More informationWhat is the menopause?
Dr Robyn Leake What is the menopause? Permanent cessation of ovarian production of follicles and female hormones Clinically no periods for 12 months Can be assessed by day 2 FSH and LH Perimenopause is
More informationMenopause & Hormone Therapy
Menopause & Hormone Therapy The Verdict! In 2012 there were two important medical articles that brought clarity to a decade of fear and confusion regarding the risks and benefits of hormone therapy in
More informationBio-Identical Hormone FAQ s
Bio-Identical Hormone FAQ s What are bio-identical hormones? They are derived from a natural plant source and professionally compounded to be biologically identical to human form of estradiol and testosterone.
More informationWhat is the menopause and what are the symptoms?
What is the menopause and what are the symptoms? Strictly speaking, the menopause is the last menstrual period. However, most women think of the menopause as the time of life leading up to, and after,
More informationDEPRESSION DURING THE TRANSITION TO MENOPAUSE: A Guide for Patients and Families
DEPRESSION DURING THE TRANSITION TO MENOPAUSE: A Guide for Patients and Families David A. Kahn, MD, Margaret L. Moline, PhD, Ruth W. Ross, MA, Lori L. Altshuler, MD, and Lee S. Cohen, MD www.womensmentalhealth.org
More informationWomen & Men s Health
ChiroCredit.com/OnlineCE.com Presents: Intro To Hormones 102 Salivary Hormone Testing Part 2 Women & Men s Health Ronald Steriti, ND, PhD 2008 Salivary Hormones The following hormones are typically in
More informationGuidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP 021 Revised June, 2008 (Replaces October 2000 version)
Guidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP 021 Revised June, 2008 (Replaces October 2000 version) 1. Scope This laboratory Guideline is intended to assist community
More informationAlternatives to hormone replacement therapy for symptoms of the menopause
Information for you Published in December 2011 (next review date: 2015) Alternatives to hormone replacement therapy for symptoms of the menopause This information is for you if you are considering alternatives
More informationHormone therapy and breast cancer: conflicting evidence. Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group
Hormone therapy and breast cancer: conflicting evidence Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group The world of hormone therapy in the 1990 s Throughout the 1970s, 1980s and 1990s
More informationEFFECT OF INCREASED TESTOSTERONE LEVEL ON WOMAN S FERTILITY
1 Nada Polyclinic, Po ega, Croatia 2 School of Medicine, University of Zagreb, Zagreb, Croatia Preliminary Communication Received: April 15, 2004 Accepted: June 16, 2004 EFFECT OF INCREASED TESTOSTERONE
More informationUterus myomatosus. 10-May-15. Clinical presentation. Incidence. Causes? 3 out of 4 women. Growth rate vary. Most common solid pelvic tumor in women
Uterus myomatosus A.J. Henriquez March 14, 2015 Uterus myomatosus Definition, incidence, clinical presentation and diagnosis. New FIGO classification for uterine leiomyomas Brief description on treatment
More informationPrediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions
Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although
More informationPROVERA (medroxyprogesterone acetate) Product Monograph Page 34 of 38
PART III: CONSUMER INFORMATION PR PROVERA* (medroxyprogesterone acetate) This leaflet is part III of a three-part "Product Monograph" published when PROVERA was approved for sale in Canada and is designed
More informationFaculty of Sexual & Reproductive Healthcare Clinical Guidance
FACULTY OF SEXUAL & REPRODUCTIVE HEALTHCARE Faculty of Sexual & Reproductive Healthcare Clinical Guidance Contraception for Women Aged Over 40 Years Clinical Effectiveness Unit July 2010 ISSN 1755-103X
More informationPrevalence of menopausal symptoms among mid-life women: findings from electronic medical records
Sussman et al. BMC Women's Health (2015) 15:58 DOI 10.1186/s12905-015-0217-y RESEARCH ARTICLE Open Access Prevalence of menopausal symptoms among mid-life women: findings from electronic medical records
More informationEmergency contraception, including ellaone (based on FSRH/CEU Guidance)
Emergency contraception, including ellaone (based on FSRH/CEU Guidance) Dr Lynsey Dunckley Associate Specialist SRH Southampton Solent Sexual Health Conference Friday 25 th January 2013 Quiz! Which is
More informationEndocrinology & Women s Health + Adult Immunizations Exotic Asia CME Cruise June 15 24, 2015. Menopause & Osteoporosis update 2015.
Menopause and Osteoporosis Update 2015 Post WHI-Update CCFP, MHSc, FRCP,FCFP,, NAMS Accredited Menopause Expert Associate Professor University of Toronto www.seacourses.com 1 Canadian Population Pyramid:
More informationPOSTMENOPAUSAL ESTROGEN REPLACEMENT THERAPY
POSTMENOPAUSAL ESTROGEN REPLACEMENT THERAPY Dorie W. Schwertz, PhD (2/01) University of Illinois at Chicago Hormone Replacement Therapy (HRT) and Estrogen Replacement Therapy (ERT) Menopause - loss of
More informationTHE BREASTFEEDING ANSWER BOOK CONTRACEPTION. To download electronic version. llli.org/babupdate
THE BREASTFEEDING ANSWER BOOK 12 CONTRACEPTION March 2012 Update To download electronic version llli.org/babupdate World Health Organization recommendations Theoretically hormonal contraceptive use could
More informationThe objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand
1 The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand the factors affecting the choice of protocol based
More informationThyroid Dysfunction in Dysfunctional Uterine Bleeding
Article ID: WMC002221 ISSN 2046-1690 Thyroid Dysfunction in Dysfunctional Uterine Bleeding Corresponding Author: Dr. Veena Aseeja, Associate Professor, Obs and Gynae MMIMSR Mullana Ambala, 160104 - India
More informationSafe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer
Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Camran Nezhat,, MD, FACOG, FACS Stanford University Medical Center Center for Special Minimally Invasive
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More information7720 Rivers Edge Dr., Suite 121 Columbus, OH 43235 Ph: 614-888-8923 Fax: 614-888-8931 www.integrativehormoneconsulting.com
7720 Rivers Edge Dr., Suite 121 Columbus, OH 43235 Ph: 614-888-8923 Fax: 614-888-8931 www.integrativehormoneconsulting.com Bioidentical Hormone Replacement Therapy for Women Menstrual Cycle Days 1 5: Estrogen
More informationWhat Athletic Trainers Need to Know About Gynecology
What Athletic Trainers Need to Know About Gynecology Mona M. Shangold,, M.D. Director The Center for Women s Health and Sports Gynecology Philadelphia, PA Main Topics Normal development and function Effects
More informationGARY S. DONOVITZ, M.D., F.A.C.O.G.
Sub-Cutaneous Hormone Pellet Therapy- The Comprehensive Treatment to Optimize and Balance Hormones Using the BioTE Method GARY S. DONOVITZ, M.D., F.A.C.O.G. The BioTE method of hormone replacement is a
More informationForgetfulness is common during middle
Cognitive Symptoms and Disorders in the Midlife Woman MENOPAUSE MATTERS from www.menopause.org Victor W. Henderson, MD, MS, NCMP Given the high prevalence of cognitive complaints from middleage women,
More informationMenopause: should I take HRT?
Patient information from the BMJ Group Menopause: should I take HRT? The menopause is when your periods stop for good. It isn't an illness. It's a normal part of every woman's life. But sometimes it causes
More informationIf you are still in your fertility years If you are past your fertility years and need surgery for a mass or for pain and have normal ovaries
If you are still in your fertility years, an ovary should be removed only if there is a large, complex or persistent mass on it or if you have intolerable pain from endometriosis. There should be an attempt
More informationAssociation of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization
Association of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization Robert L. Barbieri, M.D., a Pat M. Sluss, M.D., b Robert D.
More informationPrevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus
Prevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus Hypogonadism is defined as deficient or absent male gonadal function
More informationThe normal ovary produces larger amounts of
Menopause: The Journal of The North American Menopause Society Vol. 11, No. 5, pp. 531-535 DOI: 10.1097/01.GME.0000119983.48235.D3 2004 The North American Menopause Society Text printed on acid-free paper.
More informationEFFECTIVENESS OF HORMONE REPLACEMENT THERAPY FOR VASOMOTOR SYMPTOMS IN MENOPAUSE
ORIGINAL ARTICLE EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY FOR VASOMOTOR SYMPTOMS IN MENOPAUSE Anisa Fawad, Nargis Danish Ayub Teaching Hospital, Abbottabad, Pakistan ABSTRACT Background: Vasomotor
More informationTestosterone Treatment in Older Men
Testosterone Treatment in Older Men J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships to disclose.
More informationHormone. Replacement. Therapy. Information leaflet. This information is also available on request in other formats by phoning 01387 241053.
Hormone Replacement Therapy This information is also available on request in other formats by phoning 01387 241053. Information leaflet Produced by Dr H Currie & Sr. K Martin May 2005 Updated Dec. 2013
More informationPellet Implant FAQ Provided By: Rebecca Glaser, MD, FACS www.hormonebalance.org
Understanding BHRT Pellet Implants Pellet Implant FAQ Introduction Data supports* that hormone replacement therapy with pellet implants is the most effective and the most bioidentical method to deliver
More informationSPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE
SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE David Kreiner, M. D. * Kathleen Droesch, M.D. Daniel Navot, M.D. Richard Scott, M.D. Zev Rosenwaks, M.D.
More informationRisk Management Plan
Risk Management Plan Active substance: Drospirenone/ethinylestradiol Version number: 4.0 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Oral contraception Effective control
More informationGynecologic Cancer in Women with Lynch Syndrome
Gynecologic Cancer in Women with Lynch Syndrome Sarah E. Ferguson, MD FRCSC Division of Gynecologic Oncology, Princess Margaret Hospital, University of Toronto June 11, 2013 Objective 1. To review the
More information